Pfizer’s Zyrtec Remains Strong As Rx Antihistamine Market Weakens
This article was originally published in The Tan Sheet
Executive Summary
The many loratadine products now available in the OTC market have not been able to undercut sales for Pfizer's Zyrtec (cetirizine), according to the company